Sidvim LifeSciences Private Limited

Two minutes of quick reading Pharma IP & Regulatory Roundup 2026: Blockbuster Patent Challenges and Landmark REBYOTA Decision The global pharmaceutical landscape in June 2026 continues to present complex legal strategies and high-stakes patent battles . From critical Paragraph IV challenges against blockbuster drugs to a definitive U.S. District Court verdict on damages for faecal microbiota transplantation (FMT) therapy, generic and innovator companies alike face shifting operational dynamics . Below is an analytical summary of the most impactful regulatory and intellectual property (IP) developments . 1. Day-One Paragraph IV Filings Target BMS' Blockbuster Camzyos In a major development for the generic drug industry, the USFDA's Paragraph IV database was updated on June 9, 2026, revealing that seven generic applicants simultaneously submitted Abbreviated New Drug Applications (ANDAs) with Paragraph IV certifications targeting mavacamten capsules ( 2.5 mg , 5 mg , 10...

Summary of the blog post - 2 minutes read US Generic Pharma Update 2026: May ANDA Approvals & Landmark Supreme Court IP Ruling The U.S. generic pharmaceutical sector experienced a highly active period in mid-2026, marked by a surge in regulatory clearances and a historic legal decision from the nation's highest court . In this comprehensive regulatory roundup, we break down the USFDA’s May 2026 Abbreviated New Drug Application (ANDA) approvals, highlight key product launches from top Indian manufacturers, and analyse a landmark Supreme Court patent decision that reshapes the legal landscape for generic drug entry . 1. USFDA May 2026 ANDA Approvals Analysis Overview The USFDA maintained a high  pace of regulatory reviews in May 2026, issuing a total of  65 ANDA approvals , of which  20 were tentative . What is a Tentative Approval? A tentative approval indicates that a generic drug application has fully met all of the USFDA’s rigid scientific, quality, safety, and...